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The limited induction of Th1 and cytotoxic immune responses is regarded as the main reason for the increased
susceptibility to intracellular microorganisms in early life. Recently, in vitro IL-12 supplementation was shown to enhance the
limited IFN-g release of measles-specific infant T cells. Using a series of IL-12 delivery systems, we show here that in vivo
IL-12 supplementation may enhance early life murine Th1 responses to two model vaccine antigens, measles virus
hemagglutinin and tetanus toxin peptide. However, this required multiple repeat injections of recombinant rIL-12, which were
poorly tolerated in young mice. Local IL-12 delivery by an IL-12 expressing canarypox vector proved safe but failed to
modulate vaccine responses. An IL-12 DNA plasmid or a CD40L DNA plasmid efficiently enhanced neonatal Th1 responses
to measles hemagglutinin DNA vaccine. However, both plasmids only enhanced Th1 responses to DNA and not to peptide,
protein, or live viral vaccines. Thus, inducing adult-like Th1 responses may be achieved in vivo by inducing (CD40L) or
substituting for (IL-12 supplementation) optimal activation of neonatal APC. However, these immunomodulatory effects
appear limited to certain antigen-presentation approaches and may not be broadly applicable to vaccines. © 2000 Academic
Press
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IINTRODUCTION
Newborns and infants show an enhanced susceptibil-
ity to infectious diseases, reflecting the immaturity of
their defense mechanisms against pathogens. Differ-
ences between adult and early life responses have been
reported for both innate and antigen-specific immunity
(Kovarik and Siegrist, 1998). In particular, early life T cell
responses are characterized by reduced IFN–g produc-
tion when compared to adult responses, both in mice
(Adkins et al., 1993; Adkins and Hamilton, 1992) and in
humans (Lee et al., 1996; Scott et al., 1997). The lack of
Th1 and CTL responses are likely to be responsible for
the increased susceptibility to intracellular pathogens,
such as Herpes simplex, measles, RSV, mycobacterium
tuberculosis, and Listeria monocytogenes, hampering
their rapid elimination.
As an example, a limited production of IL-12 by neo-
natal APC and subsequent low IFN-g vaccine responses
o measles have been observed in early life, both in
urine models (Barrios et al., 1996b; Kovarik et al., 1999)
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122and recently in human infants (Gans et al., 1999). This is
considered to largely reflect suboptimal activation of
neonatal antigen presenting cells (APC) such as macro-
phages and dendritic cells (DC), rather than intrinsic
limitations of early life T cells. Indeed, adult-like neonatal
murine Th1 responses to various antigens could be in-
duced in early life using selected Th1-driving antigen
delivery systems such as adult dendritic cells (Ridge,
Fuchs, and Matzinger, 1996), strong Th1 driving adju-
vants (Barrios et al., 1996a; Forsthuber et al., 1996), live
replicating agents (Sarzotti et al., 1996; Siegrist et al.,
1998b), plasmid DNA (Martinez et al., 1997), or CpG-
ontaining oligonucleotides (Kovarik et al., 1999). These
esults indicate that induction of Th1 and CTL responses
n early life is achievable when optimal APC/T cell inter-
ction is provided.
IL-12, a product of activated APC/DC, is an essential
ytokine in the generation of the Th1 phenotype, as
eviewed in Trinchieri (1995). Apart from activating di-
ectly IL-12R expressing target cells, IL-12 enhances its
wn expression by APC/DC in an autocrine fashion
Kelleher and Knight, 1998) and acts synergistically with
FN–g on Th1 differentiation. Furthermore, the CD40/
CD40L interaction leads to the activation of APC, result-
ing in increased production of IL-12 (Kennedy et al.,
1996). Many studies have shown the capacity of IL-12 to
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123IL-12 SUPPLEMENTATION STRATEGIES IN EARLY LIFEmodulate adult immune responses in experimental mod-
els of autoimmunity, infectious diseases, and/or vaccina-
tion strategies. Precisely, Th1 responses to soluble pro-
teins antigens are elicited only in the presence of IL-12,
whereas certain viral infections, such as with LCMV and
VSV, can induce protective Th1 immunity even in IL-12-
deficient mice (Oxenius et al., 1999). Recently, IL-12 was
resented as a potent neonatal vaccine adjuvant, based
n results obtained in newborn mice with the DNP–
valbumin (DNP-OVA) and hen eggwhite lysozyme (HEL)
odel antigens (Arulanandam et al., 1999). More impor-
antly, in vitro supplementation of IL-12 was reported as
apable of enhancing the limited IFN-g responses of
infant T cells to measles vaccine, supplementing the
limited capacity of IL-12 production by infant APC (Gans
et al., 1999).
In this report, we examine whether in vivo IL-12 sup-
plementation or CD40 activation could induce early life
Th1-type immune responses to measles hemagglutinin
or tetanus toxin antigens. We used a series of delivery
systems to determine experimental conditions under
which exogenous IL-12, provided as recombinant mole-
cule or encoded by a viral vector or a bacterial DNA
plasmid, could enhance Th1 measles vaccine responses
in early life.
RESULTS
Effects of recombinant IL-12 on neonatal immune
responses
We studied the capacity of rIL-122 to enhance Th1-type
neonatal immune responses using a representative
panel of vaccine antigens and delivery systems in
2 Abbreviations used: ALVAC, recombinant canarypox virus; HA,
easles-hemagglutinin; MVS, measles vaccine (Schwarz-strain);
cDNA3, control plasmid; pCD40L, plasmid expressing CD40L; pIL-12,
lasmid expressing murine IL-12; rIL-12, recombinant murine IL-12;
FIG. 1. Cytokine secretion by splenocytes from 1-week-old mice immu
of 1 mg of rIL-12 or PBS. Splenocytes were recovered 3 weeks postim
means and the SD of groups of 6 to 8 individual mice per group fromm
MV-HA, plasmid expressing a secreted form of measles HA; TTP30,
etanus toxin immunodominant peptide.1-week-old Balb/c mice, an age that best correlates with
immune maturation of human newborns (Siegrist, in
press). Mice were first immunized with a model peptide
antigen, an AlOH-adjuvanted immunodominant tetanus
peptide (TTP30) that preferentially induces Th2-type im-
mune responses in early life (Barrios et al., 1996a). TTP30
was administered i.p. with 1 mg of rIL-12 or PBS (negative
ontrols). When antigen specific T cell responses were
ssessed 3 weeks after immunization, absence of IFN-g
and persistent high IL-5 production by antigen-specific T
cells (Fig. 1) indicated that exogenous rIL-12 had failed to
modulate neonatal TTP30 T cell cytokine responses.
Similarly, coadministration of a single dose of rIL-12
remained without significant influence on early life T cell
cytokine responses to measles vaccine (MVS) and to live
measles–HA recombinant canarypox virus (ALVAC-HA;
data not shown).
Because the effect(s) of single-dose rIL-12 on the im-
mune response may be transient (Rempel et al., 1997),
we performed similar immunizations but with repeated
injections of rIL-12. A weight-adjusted dose of 0.1 mg of
rIL-12 for 1-week-old mice and 1 mg of rIL-12 for adult
mice was injected i.p. 24 h before TTP30 priming and on
days 0, 11, and 12 after priming. This iterative rIL-12
supplementation enhanced early life Th1-type vaccine
responses to the injected antigen, as indicated by the
significant increase in the production of IFN–g and some
reduction in IL-5 responses by antigen specific T cells of
treated mice compared to those of mice immunized with
antigen but without exogenous rIL-12 (Table 1). In spite of
the usual dispersion of biological values measured in
early life, the cytokine responses of TTP30-specific T
cells of neonatal mice were now similar to those of
TTP30-specific T cells induced in adult mice. This strat-
egy of repeat rIL-12 injections successfully enhanced
IFN–g production by early life measles-specific T cells
following measles immunization (MVS, Table 1), increas-
ith AlOH-adjuvanted TTP30 peptide and coinjected with either 1 dose
tion and restimulated with antigen for 72 h in vitro. Indicated are the
sentative experiment.nized wing the IFN–g/IL-5 ratio of rIL-12-treated 1-week-old
ice, although not to values observed in adult mice.
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124 KOVARIK ET AL.Multiple injections of rIL-12 with TTP30-priming signif-
icantly enhanced the production of TTP30-specific IgG,
IgG1, and IgG2a in adult mice (Fig. 2A). In contrast, we
could barely detect TTP30-specific antibodies in mice
immunized at 1 week of age, regardless of exogenous
rIL-12 supplementation (Fig. 2A). However, when mice
primed at 1 week of age were boosted 5 weeks later with
TTP30 alone, in order to expand their primary B cell
responses, we detected TTP30-specific IgG2a in three of
five pups that received rIL-12 at time of priming, com-
pared to none of the PBS-supplemented control mice
(Fig. 2B). Total IgG titers after MVS priming of 1-week-old
mice were similar in the rIL-12-supplemented group
(log10 3.4 6 0.7) as in the PBS-supplemented controls
log10 3.9 6 0.1) and rIL-12 coimmunization resulted only
n a very moderate, not significant, increase of IgG2a
iters in some, but not all, pups (data not shown). Thus,
ultiple doses of exogenous rIL-12 in early life did prime
h1-driven IgG2a B cells, but failed to enhance primary
ntibody responses in early life.
A major limitation of providing rIL-12 in the neonatal
etting was its toxicity. Whereas no toxicity was ob-
erved in adult or young mice that received a single dose
f rIL-12 (up to 1 mg) or in adult mice that received four
uccessive injections of 1 mg/day of rIL-12, we observed
mild-to-moderate toxicity in 1-week-old mice following
multiple injections of as little as 0.1 mg of rIL-12. This
T
Effect of Multiple Coadministration of rIL-12a with TTP30b or Live
after Immunization of Mice and Restim
1-week-old controls 1-week
TTP30,
IFN-g 120 6 72* 720
IL-5 1235 6 1055** 452
IFN-g/IL-5c 0.10
TTP30,
IFN-g 512 6 256*** 1528
IL-5 2439 6 1700 1548
IFN-g/IL-5c 0.21
IFN-g 1239 6 359* 2679
IL-5 3701 6 1572 2203
IFN-g/IL-5c 0.33
Note. Cytokines were measured in the supernatants by ELISA. Indica
mice obtained in representative experiments. Cytokine levels are expr
a rIL-12 was administered on days 21, 0, 11, and 12; controls rec
b TTP30 peptide was adsorbed onto AlOH as indicated under Mat
c IFN-g/IL-5 ratio, indicative of Th1/Th2 balance.
* and ** P , 0.02.
*** P , 0.05.toxicity was reflected by the suboptimal weight gain of
treated animals compared to that seen in animals in-jected with PBS (Fig. 3). We also observed significant
mortality in 1-week-old mice that were given multiple
injections of higher amounts of rIL-12, such as 0.2, 0.5, or
1 mg per dose. Thus, the therapeutic index of rIL-12 in
eonatal mice appears very low.
L-12 delivery by a canarypox vector encoding IL-12
ails to modulate immune responses
To avoid the requirements for multiple injections of
IL-12 and limit their systemic adverse effects, we exam-
ned whether a canarypox vector encoding IL-12 (ALVAC-
L12) could modulate vaccine responses when coin-
ected with antigen. Previous studies demonstrated that
ntratumor injection of ALVAC-IL12 could reduce the
rowth of tumors in adult mice (Puisieux et al., 1998).
owever, coadministration of 1 3 106 TCID50 of ALVAC-
IL12 with antigen failed to modulate the neonatal Th1/
Th2-type responses to either TTP30 (Fig. 4), MVS, or
ALVAC-HA (data not shown). Coinjection of ALVAC-IL12
also failed to enhance Th1-type immune responses to
either of these antigens in adult mice. In addition, coin-
jection of 1-week-old mice with TTP30 and four doses of
ALVAC-IL12 at 1 3 106 TCID50 on days 21, 0, 11, and 12
of immunization failed to influence a detectable change
on the T cell responses (data not shown). Thus, supple-
ntigen on Cytokine Secretion by Splenocytes Recovered 3 Weeks
for 72 h with the Respective Antigen
rIL-12 Adult controls Adults 1 rIL-12
ent 1
6* 648 6 400 1104 6 32
4** 740 6 509 544 6 138
0.88 2.03
ent 2
6*** ND ND
7 ND ND
0* 4040 6 2216 ND
1 665 6 943 ND
6.08
the means and standard deviations of groups of six to eight individual
in pg/ml for IFN-g and IL-5. ND, not done.
the same volume of PBS.
d Methods.ABLE 1
MVS A
ulated
-old 1
experim
6 81
6 73
1.59
experim
6 101
6 99
0.99
MVS
6 63
6 44
1.21
ted are
essed
eived
erial anmentation of IL-12 by this canarypox vector, which was
well tolerated even following multiple administration in
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125IL-12 SUPPLEMENTATION STRATEGIES IN EARLY LIFEvivo, failed to significantly modulate all vaccine re-
sponses tested.
Delivery of IL-12 by plasmid DNA enhances Th1-type
neonatal immune responses to measles DNA
vaccines but not to conventional vaccine antigens
We examined whether coinjection of plasmid DNA
encoding murine IL-12 (pIL-12) with antigen could mod-
ulate the immune response to antigens in neonatal mice,
as previously shown for adult mice (Chow et al., 1998;
Kim et al., 1998a). The coimmunization of 1-week-old
FIG. 2. (A) Anti-TTP30 serum antibody titers at 3 weeks after primary
immunization of either 1-week-old mice or adult mice immunized with
AlOH-adjuvanted TTP30 peptide and coinjected with either four doses
of 0.1 mg or 1mg (adults) of rIL-12 or PBS (on days 21, 0, 11, 12).
ndicated are the mean titers and the SD of groups of 6 to 8 individual
ice. (B) Anti-TTP30 serum antibody titers at 4 weeks after booster
mmunization. One-week-old mice or adult mice (PBS controls only)
ere primed with AlOH-adjuvanted TTP30 peptide and coinjected with
ither 4 doses of 0.1 mg of rIL-12 or PBS (on days 21, 0, 11, 12). Five
weeks after the primary immunization the same mice were boosted
with AlOH-adjuvanted TTP30 peptide alone. Indicated are the mean
titers and the SD of groups of five to seven individual mice.mice with pIL-12 failed to increase IgG responses to all
MV-HA DNA vaccines tested (data not shown). Injectionof 1-week-old mice with a plasmid encoding a mem-
brane-bound MV-HA (mMV-HA, 100 mg) induced adult-
like exclusive Th1(IFN–g) and CTL responses, as previ-
ously described (Martinez et al., 1997). These responses
were not further enhanced by coinjection with a plasmid
encoding pIL-12 (100 mg) (data not shown). In contrast,
i.m. injection of 1-week-old mice with a plasmid encod-
ing a secreted form of measles–HA (sMV-HA, 100 mg)
nduced the generation of T cells that produced high
evels of IL-5 and IFN–g in response to antigen, a cyto-
kine pattern that differed from the exclusive Th1 (IFN–g)
responses following adult immunization (Table 2). Coin-
jection of 1-week-old mice with plasmid encoding
sMV-HA along with a plasmid encoding pIL-12 (100 mg)
led to cytokine patterns where T cells produced signifi-
cantly less IL-5 (experiment 1), more IFN–g (experiment
), or both (experiment 3), compared to T cells from
ontrol mice that were injected with sMV-HA and the
cDNA3 control plasmid (Table 2). Thus, coinjection of
MV-HA with a plasmid encoding IL-12 consistently en-
anced IFN-g/IL-5 ratios of responses to sMV-HA DNA,
lthough not to adult levels. CTL responses to sMV-HA in
ice primed at 1 week of age, already in the absence of
IL-12 supplementation, were as high as those in mice
rimed in adulthood (data not shown). In striking con-
rast, however, coinjection of pIL-12 with any one of a
anel of non-DNA, conventional vaccine antigens such
s MVS (Table 2) or TTP30 (not shown), failed to modu-
ate the antigen-specific immune response in young
ice.
oinjection of plasmid DNA encoding CD40L reduces
he Th2-type neonatal immune responses to DNA
accines but not to conventional vaccine antigens
We also examined whether coinjection of vaccine an-
igens with anti-CD40 mAbs or a plasmid encoding
FIG. 3. Body weight of 1-week-old mice immunized with AlOH-
adjuvanted TTP30 peptide and coinjected with four doses of 0.1 mg of
rIL-12 or PBS (on days 21, 0, 11, 12). Indicated are the means and the
SD of six individual mice of each litter.
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w
e
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126 KOVARIK ET AL.CD40L (pCD40L) could modulate the immune response
to antigen in neonatal mice. Injections of two different
activating anti-CD40 mAbs (3/23 and FGK45) failed to
modulate the immune response to MVS and TTP30 in
1-week-old mice under the experimental conditions used
(data not shown). In contrast, coinjection of pCD40L
(Mendoza et al., 1997) with the sMV-HA DNA vaccine
FIG. 4. Cytokine secretion by splenocytes from 1-week-old mice i
ALVAC-IL12 (1 3 106 TCID50) or PBS. Splenocytes were recovered 3 wee
are the means and the SD of groups of six to seven individual mice.
T
Effect of Coimmunization of Plasmid Expressing IL-12 (
to HA-Expressi
1-week-old 1 pcDNA3 1-week
sMV-HA
IFN-g 2592 6 1687 2490
IL-5 3582 6 1710* 664
IFN-g/IL-5a 0.72
sMV-HA
IFN-g 1849 6 1406** 5460
IL-5 983 6 735 561
IFN-g/IL-5a 1.88
sMV-HA
IFN-g 2712 6 1260** 3851
IL-5 1079 6 603** 415
IFN-g/IL-5a 2.51
MV
IFN-g 2434 6 635 2510
IL-5 1759 6 669 2909
IFN-g/IL-5a 1.38
Note. Splenocytes were harvested 4 weeks after immunization of 1-w
ere measured in the supernatants by ELISA. Indicated are the means
xperiment, 1-week-old mice were immunized with AlOH-inactivated M
n pg/ml for IFN-g and IL-5. ND, not done.
a IFN-g/IL-5 ratio.
* P , 0.05.
** P , 0.02.induced antigen-specific T cells that produced signifi-
cantly lower amounts of IL-5, but not more IFN–g, com-
pared to 1-week-old mice injected with sMV-HA and
control pcDNA3 (Table 3). Again, injection of pCD40L
along with conventional vaccine antigens failed to mod-
ulate the antigen specific IFN–g/IL-5 balance compared
to control mice injected with antigen and control
ed with AlOH-adjuvanted TTP30 peptide and coinjected with either
timmunization and restimulated with antigen for 48 h in vitro. Indicated
or Control Plasmid (pcDNA3) on Cytokine Responses
mid (sMV-HA)
pIL-12 Adults 1 pcDNA3 Adults 1 pIL-12
iment 1
2 4080 6 2204 5762 6 7119
8* 225 6 168 234 6 189
18.13 24.62
iment 2
1** ND ND
2 ND ND
iment 3
4** ND ND
9** ND ND
H)
6 ND ND
1 ND ND
or adult mice and restimulated for 72 h with measles virus. Cytokines
ndard deviations of groups of six to eight individual mice. In the control
coadministered with pIL-12 or pcDNA3. Cytokine levels are expressedmmunizABLE 2
pIL-12)
ng Plas
-old 1
, exper
6 159
6 30
1.59
, exper
6 293
6 34
9.73
, exper
6 169
6 25
9.28
S (AlO
6 103
6 136
0.86
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127IL-12 SUPPLEMENTATION STRATEGIES IN EARLY LIFEpcDNA3, as illustrated for MVS in Table 3. It should be
noted that MVS immunization together with either
pCD40L or control pcDNA3 reverted the preferential IL-5
responses usually observed following MVS immuniza-
tion of 1-week-old mice. This is considered as reflecting
the Th1-driving adjuvant effect of immunostimulatory se-
quences present on both bacterial DNA plasmids, in
accordance with observations obtained following early
life MVS immunization with CpG-ODN (Kovarik et al.,
1999).
DISCUSSION
A limited production of IL-12 by neonatal APC and
subsequent low IFN-g vaccine responses to measles
have been observed in early life, both in murine models
(Kovarik et al., 1999) and recently in human infants (Gans
et al., 1999). Although vaccine-induced pathogen-specific
antibodies contribute to protection against most infec-
tious agents, Th1 type and CTL responses are important
particularly for the protection against intracellular patho-
gens and their generation must be taken into consider-
ation when developing vaccination strategies intended
to enhance early life vaccine responses. This is illus-
trated by the reduction of the severity of measles even in
vaccinated children who failed to seroconvert after im-
T
Effect of Coimmunization of Plasmid Expressing CD40L (
Induced by HA-Expressing Plasmid (sMV-HA) or
1 week 1 pcDNA3
sMV-HA
IFN-g 2870 6 974
IL-5 1662 6 977*
IFN-g/IL-5b 1.72
sMV-HA
IFN-g 2979 6 735
IFN-5 833 6 365*
IFN-g/IL-5b 3.57
IFN-g 5589 6 2611
IL-5 1047 6 251
IFN-g/IL-5b 5.34
Note. Splenocytes were harvested 4 weeks after immunization of 1-w
ere measured in the supernatants by ELISA. Indicated are the mean
xperiment. In the control experiment, 1-week-old and adult mice were
re expressed in pg/ml for IFN-g and IL-5. ND, not done.
a Same control group as in Table 2 (simultaneous experiment).
b IFN-g/IL-5 ratio, indicative of Th1/Th2 balance.
c Adult mice immunized with MVS without pcDNA3.
* P , 0.02.munization. This characteristic gains even more impor-
tance in the view of the fact that efficient T cell primingstill occurs even in the presence of pathogen-specific
antibodies of maternal origin, which often interfere with
the induction of antibody responses after vaccination in
young infants (Siegrist et al., 1998a). In this study, we
found that exogenous IL-12 could modulate the response
to measles or tetanus antigens toward that of a Th1-type
response when given at the time of antigen priming in
young mice. However, we found that there are several
limitations to the use of exogenous IL-12 in early life.
A single injection of rIL-12 failed to enhance the Th1-
type immune response to any of a panel of vaccine
antigens (i.e., tetanus peptide, measles vaccine, live re-
combinant canarypox virus expressing measles HA) in
1-week-old mice. This contrasts with the recent demon-
stration that a single dose of exogenous rIL-12 could
induce Th1-type immune responses to DNP-OVA and
HEL in neonatal mice (Arulanandam, Van Cleave, and
Metzger, 1999). However, it should be noted that these
authors reported a modest (2.3-fold) increase in total
splenic IFN-g (and IL-10) mRNA levels measured 2 days
after rIL-12 treatment and did not measure direct cyto-
kine production by antigen-specific T cells, as in our
study. This suggests that a single dose of rIL-12 induces
a rather limited and transient IFN-g response (Rempel et
al., 1997). Indeed, the failure of a single dose of rIL-12 to
L) or Control Plasmid (pcDNA3) on Cytokine Responses
s Virus (MVS: Control Experiment) Immunization
1 week 1 pCD40L Adult 1 pcDNA3
iment 1
2177 6 1225 4080 6 2204a
264 6 240* 225 6 168a
8.24 18.13
iment 2
1941 6 951 ND
424 6 241* ND
4.57
6793 6 3576 5592 6 1712c
1261 6 400 398 6 133c
5.38 14.08
or adult mice and restimulated for 72 h with measles virus. Cytokines
standard deviations of groups of six to eight individual mice for each
ized with MVS coadministered with pIL-12 or pcDNA3. Cytokine levelsABLE 3
pCD40
Measle
, exper
, exper
MVS
eek-old
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immunmodulate early life immune responses may be second-
ary to its transient influence on the development of such
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128 KOVARIK ET AL.responses, since repeat injections could enhance the
generation of Th1-type immune responses. In addition to
the complexity of an immunization strategy that would
require multiple injections, we observed that repeated
injections of IL-12 are toxic in young mice, as reflected by
suboptimal weight gain or even mortality. Such IL-12-
mediated toxicity has previously been reported in adult
mice after repeated injections of high doses of rIL-12 and
were associated with elevated levels of circulating
TNF-a (Orange et al., 1995). Thus, exogenous rIL-12 does
ot compare favorably, in terms of both efficacy and
olerability, with other Th1-driving adjuvants such as
pG-rich oligonucleotides, which were able to induce
dult-like early life Th1-responses to the same measles
nd tetanus vaccines (Kovarik et al., 1999).
Exogenous rIL-12 also exerted only modest adjuvant
ctivity on early life antibody responses to antigen. The
nfluence of exogenous rIL-12 on adult antibody re-
ponses may be either suppressive (McKnight et al.,
994; Morris et al., 1994) or enhancing (Jankovic et al.,
1997), and the reason for this antigen-specific contrasted
influence is not yet clear. In our models, we observed an
enhancement of antigen-specific IgG1 and IgG2a anti-
body response to TTP30 following adult immunization.
This was, however, not achieved in early life, even
though we could demonstrate IgG2a-B cell priming.
These results agree with those of Arulanandam et al.,
which demonstrated that rIL-12 could enhance the anti-
gen-specific antibody responses only in adult mice (Aru-
lanandam et al., 1999). Thus, IL-12 supplementation strat-
egies capable of inducing adult-like T cell responses did
not meet the challenge of inducing the rapid and strong
antibody responses that would be required for early life
protection against a number of pathogens, at least with
the antigens tested. This suggests the persistence of an
age-related impairment of either the communication be-
tween immature T and B cells or of T cell-independent B
cell differentiation in spite of enhanced APC/T cell inter-
action.
We expected that a more targeted delivery of IL-12
would reduce the adverse effects of iterative rIL-12 in-
jections. This was attempted first with the live recombi-
nant viral vector ALVAC-IL12. Indeed, no toxicity was
observed even following administration of ALVAC-IL12 at
high doses over 4 consecutive days in 1-week-old mice.
However, despite the use of a wide range of ALVAC-IL12
doses, this strategy failed to enhance Th1-type immune
responses to vaccine antigens. This is considered un-
likely to be due to transient expression of IL-12 by ALVAC
since this expression was reported (Puisieux et al., 1998)
o be maintained during 3–4 days, i.e., probably as least
s long as the in vivo half-life of rIL-12. The lack of
nfluence of ALVAC-IL12 on T cell responses to antigens,
bserved even when used in combination with another
LVAC vector (ALVAC-HA), is in accordance with obser-
ations indicating only successful modulation of influ-nza vaccine responses by cytokine-encoding fowlpox-
erived vectors when both vaccine antigen and cytokine
ere encoded in the same vector (Hogan et al., 1998;
eong et al., 1994). It suggests that cytokine delivery
ust occur at high level within a very narrow microen-
ironment, and possibly at the exact DC/T cell interaction
ite, in order to be efficient. It would be interesting to test
n our early life vaccine models constructs able to deliver
L-12 during a more prolonged period and with a wider
istribution, such as the adenovirus vector that was
hown to protect adult Balb/c mice from Leishmania
ajor infection (Gabaglia et al., 1999).
One of the major advantages of DNA vaccines is their
apacity for prolonged local delivery (Robinson and
orres, 1997). The coinjection of DNA vectors encoding
or immunomodulatory molecules, including cytokines
uch as IL-12, has been reported as being capable of
odulating immune responses to various experimental
NA vaccines in adult mice (Iwasaki et al., 1997; Kim et
al., 1998b). Similarly, we show that coadministration of
pIL-12 DNA was able to downmodulate neonatal Th2
responses and enhance Th1-type immune response to
transgene antigens encoded by a coinjected plasmid,
although not to adult-like level. Thus, prolonged produc-
tion of minute quantities of interleukin after DNA trans-
fection, as reported for IL-10 compared to vaccinia virus
or herpes simplex virus-based approaches (Chun et al.,
1999), may be more efficient for modulation of APC/T cell
interactions than a single administration of a large
amount of cytokine. Similarly, a prolonged activation sig-
nal may be required for the activation of neonatal APC by
CD40 ligation. Although systemic administration of anti-
CD40 mAbs failed to modulate early life immune re-
sponses, under the experimental conditions used, a
plasmid encoding CD40L significantly reduced the high
IL-5 production of antigen-specific early life T cells to
sMV-HA DNA. This indicates that the limited IL-12 pro-
duction by early life APC, and the subsequent Th2 po-
larization of vaccine responses, may be at least partly
circumvented by optimal activation of neonatal APC
through the CD40 pathway. Based on the limited data
available, we observed that CD40 ligation, in contrast to
IL-12 supplementation, was not able to increase IFN-g
production by antigen-specific T cells. This suggests
either that less IL-12 is available in situ after CD40
activation than after exogenous IL-12 supplementation
(Bianchi et al., 1999) or failure of CD40-mediated activa-
tion to fully activate neonatal APC up to adult levels.
Nevertheless, our results demonstrate an important role
for the CD40 activation pathway in early life, in agree-
ment with the previous observation that CD40 activation
by monoclonal antibodies could break neonatal toler-
ance to alloantigens presented by adult APC (Flamand et
al., 1998). Whether suboptimal CD40–CD40L interaction
in early life primarily results from the reduced expression
of CD40L at the surface of activated T cells (Arulanan-
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1998; Nonoyama et al., 1995) or whether it is the reduced
IL-12 production by suboptimally activated neonatal APC
that primarily contributes to weak CD40L expression on
T cells (Peng et al., 1998) remains an open question.
Whatever the primary mechanism, pIL-12 or pCD40L
coadministration appeared to influence the immune re-
sponses only to DNA vaccines. Coinjection of either
plasmid along with conventional peptide, protein or live
viral vaccines failed to influence the resulting immune
response. There are indeed very few published reports
of successful modulation of vaccine responses to con-
ventional vaccines by cytokine-encoded DNA vectors
(Gurunathan et al., 1998; Raz et al., 1993). This limitation
could be partly of a kinetic nature, since the timing of
recruitment of T cell responses to non-DNA vaccines is
short (less than 4 days (Bousso et al., 1999)), whereas
more time may be needed for cytokine expression/trans-
port to site of APC/T cell interaction following DNA trans-
fection. Alternatively, a different localization of DC/T cell
interactions following DNA vs non-DNA vaccine injection
may explain the differences in the susceptibility to cyto-
kine modulation by DNA vectors.
In conclusion, although direct activation of neonatal
APC by the CD40 pathway or IL-12 supplementation is
demonstrated here as critical event in inducing Th1 mea-
sles or tetanus-specific vaccine responses in early life,
these effects were limited to some selected antigen-
presentation approaches and not broadly applicable to
conventional vaccines (Table 4). This calls for further
development of novel adjuvants/immunization strategies
capable of inducing optimal activation of neonatal APC
without causing excess reactogenicity, a particularly
challenging situation in early life.
MATERIALS AND METHODS
Mice
TABLE 4
Summary of IL-12 and CD40L Supplementation Strategies for Early
Life Vaccinations with Various Antigen Presentation Systems
Strategy Antigen Observations
ingle dose rIL-12 TTP30; (MVS; ALVAC-HA) No influence
ultiple dose rIL-12 MVS; TTP30 IFN-g/IL-5 ratio1
TTP30 IgG2a1
LVAC-IL12 TTP30; (MVS; ALVAC-HA) No influence
IL-12 DNA MVS; (TTP30) No influence
sMV-HA DNA IFN-g/IL-5 ratio1
Anti-CD40 mAb (MVS; TTP30) No influence
pCD40L (MVS) No influence
sMV-HA DNA IFN-g/IL-5 ratio1
Note. Data not shown for antigens in parentheses.Specific pathogen-free adult Balb/c inbred mice were
purchased from Biological Research Laboratories (Fu¨l- Mlinsdorf, Switzerland) and kept under specific pathogen-
free conditions. Breeding cages were checked daily for
new births, and the day of birth was recorded as the day
the litter was found. Pups were kept with mothers until
weaning at the age of 4 weeks. Mice were considered as
adults when they were more than 8 weeks of age.
Immunization procedures
The immunodominant epitope of tetanus toxin peptide
TTP30 (Barrios et al., 1996b) was used in a concentration
of 100 mg per dose and was injected i.p. The peptide was
dsorbed to AlOH (Chiron Vaccines, Siena, Italy) imme-
iately prior to immunization using 0.25 mg AlOH for
oung mice and 1 mg for adult mice. Live attenuated
easles virus (Schwarz strain (MVS), 5 3 105 CCID50 per
ose) was obtained from Pasteur Me´rieux Connaught
Marcy l’Etoile, France) and was used either live or inac-
ivated with AlOH, as indicated in the legends. Live
ecombinant canarypox virus expressing the measles
irus hemagglutinin (HA) (vCp85, ALVAC-HA, 5 3 107
PFU per dose) was generously provided by Dr J. Tarta-
glia, Virogenetics Inc. (Troy, NY). Both measles vaccines
were injected either i.p. or i.m. (when coimmunized with
plasmid antigens). The bacterial plasmid pV1J-HA en-
coding the secreted form of measles virus HA was pre-
viously described (Cardoso et al., 1996) and was injected
at a dose of 100 mg per mouse i.m.
Murine recombinant IL-12 (rIL-12) was a generous gift
from Dr M. Gately (Hoffmann LaRoche, Nutley, NY) and
was administered separately at the indicated doses in
PBS containing 1% Balb/c mouse serum. Bacterial plas-
mids expressing the murine gene for IL-12 (Lee et al.,
1998) and CD40L (Mendoza et al., 1997) were described
previously and were used at a dose of 100 mg per mouse
njected i.m. Control mice were coimmunized with 100
mg of the pcDNA3 plasmid (Invitrogen, Carlsbad, CA).
ALVAC-IL12 (murine) was obtained from Dr B. Meignier,
(Pasteur Me´rieux Connaught, Marcy l’Etoile, France) and
was used at 1 3 106 TCID50 per dose and mouse. Its
capacity to deliver the IL-12 gene was confirmed by
detecting murine IL-12 (IL-12p70; ELISA-kit from Pharm-
ingen, San Diego, CA) in supernatants of ALVAC-IL12-
infected Ltk fibroblasts (Puisieux et al., 1998). Anti-CD40
mAb (clone 3/23) was purchased from Pharmingen and
doses of 10 mg were injected i.p. in 1-week-old mice on
days 1 and 3 postimmunization with MVS or TTP30 (Fla-
mand et al., 1998). Anti-CD40 mAb (clone FGK45) was
generously provided by Dr. A. Rolink (Basel Institute for
Immunology, Basel, Switzerland) and 1-week-old mice
were injected i.p. with either 0.5 mg of mAb on days 0
and 1 post immunization with MVS or with 0.25 mg of
mAb on days 21, 0, 11, and 12 postimmunization with
VS (Rolink et al., 1996; Schoenberger et al., 1998).
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130 KOVARIK ET AL.Quantification of vaccine-specific antibodies
Mice were bled at regular intervals for the determina-
tion of vaccine-specific serum antibodies (Barrios et al.,
1996b). Serum TTP30 antibodies were measured by
ELISA by using antigen-coated plates and serum MV-HA
antibodies were measured by using coated plates with
Ltk-HA-transfected cells. Incubations was performed
with serial serum dilution starting at 1/100. After wash-
ing, the relevant isotype-specific peroxidase-conjugated
goat or rabbit anti-mouse antibody (Zymed Laboratories
Inc., San Francisco, CA) was added for 2 h at 37°C prior
o washing, incubation with substrate, and reading. The
esults were generated by reference to serial dilution of
titrated serum pool from immunized adult mice. Anti-
ody titers below the cutoff of the assay were being
iven an arbitrary titer of one half the cutoff in order to
llow calculation of geometric mean antibody titers.
uantification of lymphokines in supernatants
f in vitro cultures
In experiments with antigen injections, splenocytes
ere harvested 3 weeks after immunization. For the in
itro restimulation, splenocytes were incubated at 37°C
n 5% CO2 humidified incubator in DMEM supplemented
with 10% (v/v) heat inactivated fetal calf serum, 1.5 mM
L-glutamine, 50 mM 2-mercaptoethanol, 100 U/ml peni-
illin, and 100 mg/ml streptomycin, essentially as de-
cribed (Barrios et al., 1996b). Cells (10 3 106 per ml)
ere cultured in 24-well plates and coincubated with
accine antigens (10 mg/ml TTP30 peptide or 0.25 3 106
CCID50 per ml MVS) or with DMEM–10% FCS only (con-
trol wells). Cell supernatants were collected after 48 or
72 h for measure of IL-5 and IFN-g contents by capture
ELISA (Barrios et al., 1996b). Values for IL-5 and IFN-g
were expressed by reference to a standard curve con-
structed by assaying serial dilution of the respective
mouse cytokines. Values below the cutoff of the assay
(IL-5, 25 pg/ml, IFN-g, 80 pg/ml) were given an arbitrary
iter of one half the cutoff. Antigen-specific cytokine se-
retion was obtained by subtracting the cytokine content
f the supernatant from splenocytes incubated with
MEM–10% FCS alone.
tatistical analysis
Significance analysis between results obtained from
arious groups of mice was performed by using the
ann–Whitney U test. Probability values .0.05 were
onsidered insignificant.
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